← Back to Clinical Trials
Recruiting NCT07464808

NCT07464808 Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07464808
Status Recruiting
Phase
Sponsor Ain Shams University
Condition Venous Thromboembolic Event
Study Type INTERVENTIONAL
Enrollment 25 participants
Start Date 2025-11-28
Primary Completion 2027-01-30

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
follow up venous thrombo embolic events with routine clexan dose modification guided by anti factor 10 assayfollow up venous thromboembolic events with no routine clexan dosage modification and no usage of anti factor 10 assay

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 25 participants in total. It began in 2025-11-28 with a primary completion date of 2027-01-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the efficacy of anti-Xa based versus weight-based enoxaparin dosing and to evaluate anti-Xa levels as a predictive tool for clinical outcomes in burn patients

Eligibility Criteria

Inclusion Criteria: 1. Adults (≥21 years) admitted to the burn unit with thermal burns ≥20% TBSA and \< 60%. 2. Admission to BICU within 48 hours of burn injury. 3. Indication for VTE prophylaxis (e.g., immobilized, surgical intervention). 4. Ability to provide informed consent Exclusion Criteria: 1. Pre-existing coagulopathy or anticoagulant therapy prior to injury. 2. Patients with severe comorbidities (e.g., end-stage renal failure, advanced malignancy, hepatic disease). 3. Need for therapeutic anticoagulant therapy. 4. patients with extremes of weight, (45kg \>=weight \>= 150kg).

Contact & Investigator

Central Contact

Doaa Ahmed Diaa El din Ibrahim, MD

✉ Doaaeldin@med.asu.edu.eg

📞 01128904628

Frequently Asked Questions

Who can join the NCT07464808 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, studying Venous Thromboembolic Event. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07464808 currently recruiting?

Yes, NCT07464808 is actively recruiting participants. Contact the research team at Doaaeldin@med.asu.edu.eg for enrollment information.

Where is the NCT07464808 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT07464808 clinical trial?

NCT07464808 is sponsored by Ain Shams University. The trial plans to enroll 25 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology